Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation

BACKGROUND: There are few studies that directly compare the effects of osimertinib on patients with non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) T790M mutation between the generation of prior EGFR tyrosine kinase inhibitors (TKIs). METHODS: We retrospectively...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Miyashita, Yosuke, Ko, Ryo, Shimada, Naoko, Mitsuishi, Yoichiro, Miura, Keita, Matsumoto, Naohisa, Asao, Tetsuhiko, Shukuya, Takehito, Shibayama, Rina, Koyama, Ryo, Takahashi, Kazuhisa
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7862784/
https://ncbi.nlm.nih.gov/pubmed/33219754
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13742
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados